Friday, May 7, 2021
104 4 to 9 May

Ashirwad 51000

Kisani Karza 4624 Cr

Shaheed 50 lakh

Mahila Sarpanch

Vidhwa Pension 1500

NNP Soorbir

Markfed 3 3


Verka Ice Cream

Innocent Hunar Se Rozgar 25 4 21

SII borrows money from banks to scale up Covishield production

- Advertisement -

New Delhi, April 21, 2021-
To scale up production of its Covishield vaccine, the Serum Institute of India (SII) had borrowed money from banks instead of waiting for the government’s aid to arrive.

The company assumed that the funding from the government will reach them very soon, probably by this week.

Covishield has been developed by the Oxford University and AstraZeneca, and manufactured by the Pune-based SII.

To boost India’s vaccine production in wake of the huge surge in Covid-19 caseload, the government on Monday announced that it has given in-principle approval for credit to vaccine manufacturers, SII and Hyderabad-based Bharat Biotech. The Union Finance Ministry has approved a sanction of Rs 3,000 crore credit for SII and Rs 1,500 crore to Bharat Biotech.

The credit will be disbursed at the earliest.

Adar Poonawalla, CEO of Serum Institute of India, earlier had suggested that the company would require around Rs 3,000 crore to increase production of Covid-19 vaccines.

SII, an Indian biotechnology and pharmaceuticals company, on Wednesday announced that Covishield will be sold at Rs 400 per dose to the state government and Rs 600 to private hospitals. They issued the statement after the government allowed vaccination of all persons above the age of 18 from May 1.

The decision was announced following a meeting of Prime Minister Narendra Modi with pharma companies, doctors, Cabinet ministers in charge of health, drugs and officials spanning multiple nodal ministries.

Poonawalla welcomed the government’s announcement to accelerate India’s vaccination drive.

“The promising directives will help to scale up vaccine production, and allow state governments, private hospitals,and vaccination centers to procure vaccines directly,” he said.

The SII also said that for the next two months, they will address the limited capacity by scaling up the vaccine production.”Going ahead, 50 percent of our capacities will be served to the Government of India’s vaccination programme, and the remaining 50 percent of of the capacity will be for the State governments and private hospitals,” the company said.

The company also stated that considering the global vaccine prices which cost anywhere from Rs 750 to Rs 1,500 per dose, they are ensuring that vaccines are affordable in Indian comparison to any other vaccines in the world.

“Furthermore, owing to the complexity, and urgency of the situation, it is challenging to supply independently to each corporate entity. We would urge all corporate and private individuals to access the vaccines through the state facilitated machinery and private health systems,” the company stated.

Post four to five months, the vaccines will be made available in retail and free trade. (Agency)

Covishield to be sold at Rs 400 to State, Rs 600 to pvt hospitals

- Advertisement -

Yes Punjab - TOP STORIES

Punjab News

Sikh News

Transfers, Postings, Promotions

- Advertisement -spot_img

Stay Connected






COVID 19 Virus

Covid Emergency: We should go back to the districts – by DC Pathak

India is in great distress because of the 'killer' second wave of Covid and people are shaken up with the fear of the unknown...
Sri Guru Tegh Bahadar ji

Ninth Sikh Guru Tegh Bahadur led a dharmic path – by Dattatreya Hosabale

In Indian history, Guru Shri Tegh Bahadurs personality shines resplendent like a bright constellation. He was born in Amritsar to Guru Hargobindji and Nankiji...
Narendra Modi Xi Jinping

Analysis: Xi’s message to PM Modi-first step for an India-China thaw? – by Atul Aneja

New Delhi, May 1, 2021- Chinese President Xi Jinping's message on Friday to Prime Minister Narendra Modi extending Beijings support to counter the second Covid...


Health & Fitness

Coronavirus Antibodies

Decoded: How antibodies neutralise Covid infection

New York, May 5, 2021- US researchers have found how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralise the part of the virus responsible for causing Covid infection. The team from the University of Texas at Austin analysed blood plasma samples from four people who recovered from SARS-CoV-2 infections. They found that most of the antibodies circulating...

Gadgets & Tech

error: Content is protected !!